Nasdaq:SCPS

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play…

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced…

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today…

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center  Dr.…

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today…

Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc.…

CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope A Phase 1 Clinical Trial Will be Initiated at City of Hope NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today…